Regulatory T (Treg) cells are a subpopulation of T cells that not only prevent autoimmunity, but also control a wide range of T cell-dependent immune responses. Glucocorticoid treatment (dexamethasone, or Dex) has been reported to amplify IL-2-mediated selective in vivo expansion of Treg cells. We simultaneously administered Dex and IL-2 to the donor in a murine allogeneic lymphocyte transplantation model to expand functional suppressive CD4
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and to raise the regulatory T cell/effector T cell (Treg/ Teff ) ratio to prevent graft-versus-host disease (GVHD). After combined treatment of the donor with Dex (5 mg/kg/day) and IL-2 (300,000 IU/mouse/day) for 3 days, grafts were subjected to flow cytometric analysis, and transplantation was carried out from male C57BL/6 mice to female BALB/c mice aged 8 -12 weeks. Results showed that short-term simultaneous administration of Dex and IL-2 markedly expanded functional suppressive CD4
FOXP3
1 T cells in the murine spleen. In this murine allogeneic transplantation model, the grafts from donors with Dex and IL-2 pre-treatment led to a longer survival time for the recipients than for the control group (median survival time > 60 day vs. 12 day, P 5 0.0002). The ratio of Treg/Teff also increased remarkably (0.43 + + + + + 0.15 vs. 0.14 + + + + + 0.01, P 5 0.01). This study demonstrated that co-stimulation with Dex and IL-2 selectively expanded functional CD4
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Introduction
Allogeneic stem cell transplantation (SCT) remains the definitive immunotherapy for malignancy, while morbidity and mortality due to graft-versus-host disease (GVHD) remain the major barriers to its advancement [1] . The early complications of allogeneic SCT are now viewed as an allogeneic immune response primarily mediated by donor T lymphocytes with specificity against alloantigens expressed by host antigen-presenting cells in the presence of proinflammatory cytokines [2] . Up to 30% of the recipients of stem cells or bone marrow transplants from HLA-identical related donors as well as most patients receiving cells from other sources (matched, unrelated, non-HLA-identical siblings, cord blood) will develop .Grade 2 acute GVHD (aGVHD) despite immunosuppressive prophylaxis [1, 3] . Steroids, in combination with cyclosporine or, to some extent, tacrolimus, have been the standard therapy for the initial management of aGVHD. The mechanism is unclear, but is most likely related to the suppression of cytokines and lymphocytic activity [1] . About one-third of patients with aGVHD respond to initial therapy, leaving 10-50% of all patients who underwent transplants in need of secondary treatment [4] . Steroid-refractory aGVHD has a poor prognosis of ,10% survival for 1 year [5] . Polyclonal [6, 7] and monoclonal [8] [9] [10] [11] antibodies are the most widely used secondary agents and are aimed at inactivating alloreactive donor T lymphocytes, NK cells, host antigen-presenting cells, cytokines, and/or cytokine receptors. They may also be used for tissue repair in the recipient. Many controlled clinical trials found these second-line therapeutic strategies to be useful, but there is no significant benefit in terms of long-term survival, and there is apparent increase in infectious mortality [6 -11] when using this course of treatment.
Several murine studies indicated the possibility of preventing GVHD by administering naturally occurring regulatory T (Treg) cells [12] [13] [14] [15] .
Treg cells are a minor subpopulation of T cells that represent 5-10% of the normal T cell complement in mice and human [13, 16, 17] . Almost all grafts engineered for GVHD prophylaxis are generated ex vivo by the isolation and manipulation of graft subpopulations. These approaches may cause pollution, damage, and deactivation of the donor cells, thus increasing the possibility of infection. We are currently searching for a way to expand donor Treg cells in vivo to provide a novel approach for the treatment of GVHD.
Glucocorticoid (GC) treatment (dexamethasone, or Dex) has been reported by Chen et al.
[34] to amplify IL-2-mediated selective in vivo expansion of Treg cells and thereby inhibit the development of experimental autoimmune encephalomyelitis. GCs are potent antiinflammatory agents that block cytokine production. Inhibition of Jak-STAT signaling by IL-2 and related cytokines might be a mechanism of GC action [35] , suggesting that inhibition of cytokine signaling contributes to the clinical efficacy of these agents.
CD4
þ CD25 þ T cells express higher levels of glucocorticoid receptors (GRs) and Bcl-2, and are more resistant to Dex-mediated cell death than are CD4
IL-2 was identified based on its potent T cell growth factor activity and is widely considered to be a key cytokine in T cell-dependent immune responses. IL-2 is produced by activated T lymphocytes and exerts its biological effect by binding the high-affinity IL-2 receptor (IL-2R). IL-2 was found to be essential for the generation, clonal expansion, survival, and function of Treg cells [18] . Dex and IL-2 treatment C57BL/6 mice were injected daily with Dex (5 mg/kg/ day, i.p.) and/or IL-2 (300,000 IU/mouse/day, i.p.) for 3 days. The day following the last treatment, the mice were sacrificed and spleens were removed for subsequent experiments.
Mixed lymphocyte reaction
Cultures were set up in 96-well round-bottom plates (Costar, NY, USA) in a total volume of 200 ml. Cells were cultured in RPMI 1640 medium with 10% FBS, 10 mM HEPES, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO, Gaithersburg, USA). Fixed numbers of responder cells (separated from IL-2þDex pre-treatment C57BL/6 mouse or from normal C57BL/6 mouse splenocytes) and irradiated allogeneic stimulator cells (splenocytes of BALB/c mice) (10 5 cells, respectively) were mixed. At various time points (0, 3, 6 days), CCK-8 reagents were added into the culture and then the OD values were measured.
GVHD model BALB/c hosts were given total body irradiation (TBI; 500 cGy) from a Varian Clinic 600C X-ray source (Huashan Hospital, Shanghai, China) and injected with donor cells intraperitoneally within 24 h. All mice received 3-4 Â 10 7 spleen cells. The survival and appearance of mice were monitored daily and body weight was measured weekly. The degree of systemic GVHD was assessed by a scoring system [37] . After 60-80 days post-transplantation, donor lineage-specific chimerism in the transplanted animals was measured by staining host cells with anti-H-2K b and Y-chromosome polymerase chain reaction (PCR) analysis [38] .
Assessment of GVHD
The degree of systemic GVHD was assessed by a scoring system that sums changes in five clinical parameters: weight loss, poor posture (hunching), activity, fur texture, and skin integrity (maximum index ¼ 10)
[37] ( Table 1) .
Y-chromosome PCR analysis Genomic DNA was extracted from the host spleen cells using the Genomic DNA Purification Kit (TOYOBO Mag Extractor, Tokyo, Japan). Twenty-five microliters of the mixture was used per PCR reaction. Mouse SRY locus sequences on the Y chromosome in spleen cells were amplified by PCR with a specific pair of primers [38], 5 0 -CTGCTGTGAACAGACACTAC-3 0 and 5 0 -GACTCCTCTGACTTCACTTG-3 0 , resulting in a 722-bp genomic DNA fragment. Samples were heated to 948C for 5 min and then amplified for 35 cycles at 948C for 30 s, 598C for 30 s, and 728C for 1 min in 25 ml of PCR reaction mixtures. GADPH was amplified simultaneously as a control for PCR amplification with the primer pair 5 0 -CCAATGTGTCCGTCGTGGATC-3 0 and 5 0 -GCTTCACCACCTTCTTGATGTC-3 0 , resulting in a 660-bp genomic DNA fragment.
Treg expansion in vivo can suppress GVHD
Histology analysis
Formalin-preserved liver, distal small bowel, and transverse large bowel were embedded in paraffin, and 5-mm thick sections were stained with hematoxylin and eosin for histological examination.
Statistical analysis
Comparisons of data from experimental groups and the control group, and comparisons of clinical scores between the various treatment groups were analyzed with a two-tailed student's t-test using Graphpad Prism 4.0. Survival curves were plotted using Kaplan-Meier estimates. P , 0.05 was considered statistically significant.
Results
Combined Dex and IL-2 treatment selectively expands CD4
1
CD25
1 FOXP3 1 Treg cells in vivo We injected Dex (5 mg/kg/day) and/or IL-2 (300,000 IU/ mouse/day) into normal C57BL/6 mice intraperitoneally for three consecutive days, with donor mice distributed into four groups: a Dex group with Dex treatment for 3 days, an IL-2 group with IL-2 treatment for 3 days, a DexþIL-2 group with combined treatment for 3 days, and a control group of untreated mice. The percentages of CD4 þ CD25 þ donor spleen T cells and CD25 þ FOXP3 þ T cells (CD4 gated) were the highest in the DexþIL-2 group [ Fig. 1(A,B) ].
The ratio of CD4 þ CD25 þ T cells to CD4 þ CD25 2 in donor spleens was evaluated, and it was found that combined treatment with Dex and IL-2 led to a 3-fold expansion of the CD25 þ /CD25 2 ratio compared with the control group. The IL-2 or Dex group also had higher
þ /CD25 2 ratio than the control group, but either was lower than that of the DexþIL-2 group [ Fig. 1(C) ]. The ratio in the DexþIL-2 group was significantly higher than it was in the other groups (P , 0.05) [ Fig. 1(D) ].
To demonstrate whether the Treg cells expanded by IL-2 and Dex had an inhibitory effect in mixed lymphocyte reactions (MLRs), we measured the OD values of the IL-2þDex group and the negative control (NC) group at day 0, 3, and 6. It was shown that cell growth in the IL-2þDex group was slower than that in the NC group (Fig. 2) .
These results indicated that combined treatment with Dex and IL-2 markedly increased the proportion of Treg cells in the total splenic cells of the donors.
Effect of combined Dex and IL-2 treatment on Treg cells in a murine GVHD model It was found that DexþIL-2-treated donor grafts suppressed lethal aGVHD after MHC-unmatched allogeneic transplantation. Mice that received untreated donor grafts showed lethal aGVHD with the typical symptoms affecting weight, posture, activity, and fur texture [37] . Unexpectedly, recipients that received cells from Dex-treated donors showed long-term survival without GVHD symptoms. However, we failed to detect donor chimerism, indicating a failure in donor cell engraftment, so the survival and incidence for the Dex group were excluded from the statistics.
All control group mice were dead by 20 days posttransplantation with Grade 2 GVHD symptoms. The IL-2 group showed severe GVHD as well, with mortality beginning on day þ10 and continuing until all were dead by 2 weeks after the transplantation. In contrast, .70% of the DexþIL-2 group recipients survived this period, and the median survival time was .60 day (vs. control group, 12 day, P , 0.001, Fig. 3 ). Transplantation of DexþIL-2 pre-treated donor grafts resulted in the long-term survival of 52.9% (vs. 0% in the control group, P , 0.001) of the recipient mice. Clinical GVHD was also quantified using a clinical scoring system. The average clinical scores for the control group, IL-2 group, and DexþIL-2 group 14 days post-transplantation were 7.7 (n ¼ 17), 10 (dead, n ¼ 4), and 4.3 (n ¼ 17), respectively. Control animals developed severe GVHD (clinical scores . 5), which progressed over the observation period, whereas animals with Dex/IL-2 pre-treated donors had only moderate GVHD (clinical scores ranging from 3 to 5) that remained stable beyond 60 days. These results demonstrated the suppressive function of Dex/IL-2 pre-treated donor grafts both in terms of survival time and in the clinical appearance of GVHD. We also measured liver and bowel pathology in mice with and without aGVHD, as shown in Fig. 4 . Treg expansion in vivo can suppress GVHD
The incidence of lethal aGVHD increased in the IL-2 group; all recipients were dead 13 days after the transplantation. This was dependent on the administration of
2 T cells were believed to be effector T cells activated by a high dose of IL-2. 
Discussion
The immune system does indeed exhibit homeostatic organization and it must regulate itself to avert insufficient immunity while suppressing excessive responses [21] . Regulatory CD4 þ T cells that express CD25 play a vital role in the maintenance of tolerance to self-Ag and are required for the induction of non-responsiveness to allo-Ag [39] .
Investigators have found that graft Treg content may predict the risk of GVHD. Depletion of CD25 þ cells from human peripheral blood mononuclear cells (PBMCs) significantly exacerbated xenogeneic (x)GVHD and accelerated its lethality in RAG2 2/2 gc 2/2 mice, while coadministration of Treg-enriched CD25 þ cell fractions with antilogous PBMCs significantly reduced the lethality of xGVHD [20] . Murine studies have used ex vivo expanded purified CD4 þ CD25 þ T cells to suppress GVHD [23, 40] and to investigate the effects of CD4
þ CD25 2 T cells with recipient stimulator cells [14] . The expression of these regulatory molecules in grafts and recipient peripheral blood after SCT has also been examined to show that Treg content is correlated with the development and progression of GVHD [39, 41] . In this study, we used in vivo expansion of donor Treg cells to suppress GVHD, skipping the isolation, purification, and ex vivo expansion process, to provide a novel therapeutic approach using an immune prophylaxis method. One out of 17 DexþIL-2 group recipients developed a typical skin ulcer 45 days post-transplantation. This likely represented graft-versus-host reaction or light chronic GVHD. Treg infusion ahead of effector T cell treatment with a Treg/Teff ratio at almost physiological doses (1:10) allowed the persistence of effective GVL responses [15] . In our study, the Treg/Teff ratio was 1:2.33, and the clinical manifestations indicated that GVL persisted.
According to previous study, we used IL-2 and Dex at previously reported optimum doses [34] . IL-2 has been used clinically to enhance T cell immunity in patients with AIDS or cancer, and blockade with Abs to IL-2R has been used to inhibit T cell responses to transplanted tissues [42] . However, later studies discovered that IL-2 was critical for the development and peripheral mice reconstitutes the production of Treg cells and prevents lymphoproliferation and lethal autoimmunity [42, 48] . Some studies have found that using IL-2 after transplantation induced aGVHD [49] , and that blocking IL-2 signal transduction reduced the incidence of GVHD [50] . In contrast, other studies have found that IL-2 might have preventive and therapeutic effects on GVHD [51] . Thus, IL-2 has both immune stimulatory and inhibitory effects. We previously demonstrated that a low dose of IL-2 simultaneously inhibits naive T cell proliferation and differentiation to Th1 [52] . An additional study indicated that IL-2 rescues Treg cells, but not Teff cells, from Dex-mediated cell death [36] . As mentioned previously, CD4 þ CD25 þ T cells express higher levels of GR and Bcl-2, and are more resistant to Dex-mediated cell death than CD4 þ CD25 2 T cells. In comparing Treg cells to Teff cells, Tregs have higher expansion efficiency through IL-2 than Teff due to IL-2 a-chain expression and are more resistant to Dex-mediated cell death due to GR and Bcl-2 expression. We believe that there may be an intersection between the IL-2-induced proliferation pathway and the GC-induced apoptosis pathway, but this currently remains unclear.
In this study, co-administration of Dex and IL-2 selectively expanded Treg cells rather than Teff cells in vivo. 
in the DexþIL-2 group was the highest among all four groups, and it was 2-fold higher than that of the control group. The IL-2 group contained the most CD4 þ CD25 þ FOXP3 2 T cells, which are believed to be activated effector T cells induced by a high dose of IL-2.
In the future, it might be possible to engineer donor grafts that are less capable of causing GVHD by increasing Treg cells, while retaining T cell responses specific for both tumor antigens and pathogens.
In the previous study, freshly isolated CD4 þ CD25 þ T cells from unprimed animals may have prevented recipients from developing lethal GVHD after MHCunmatched allogeneic transplantation. The addition of the CD4 þ CD25 þ Treg cells at a 1:1 ratio with CD4 þ CD25 2 T cells resulted in a .90% inhibition of the mixed leukocyte reaction and marked protection from lethal GVHD [14] . In this study, recipients of DexþIL-2 pre-treated donor cells had a prolonged survival time (median . 60 day vs. 12 day for the control group) and a superior overall survival rate (52.9% vs. 0%) compared with animals transplanted with untreated donor cells. We were able to rescue more than half of the BALB/c recipients (9 out of 17) that were given cells from DexþIL-2 pre-treated donors. However, there were some differences between the experimental GVHD models applied by Hoffmann et al. [14] , and by us, including differences in the preparatory regimen (sublethal vs. lethal irradiation), and in the numbers and phenotype of the transplanted cells, which may very well account for the different outcomes of the experiments.
Severe GVHD clinical symptoms occurred in BALB/c mice that received IL-2 group donor cells; this was associated with the highest level of CD4 þ CD25 þ FOXP3 2 T cells. The Dex group mice failed in donor cell engraftment and were negative for the presence of H-2K b MHC class I and SRY-specific PCR fragments. Thus, treatment with Dex or IL-2 alone may not be the proper Treg expansion regimen.
Further studies are underway to examine the role of NK and other cells in GVHD, as well as to assess the post-transplantation GVL effect of DexþIL-2 in vivo-expanded Treg cells in malignancy disease models.
In conclusion, co-stimulation with Dex and IL-2 selectively expanded the functional CD4 þ CD25 þ FOXP3 þ T cell population in vivo, and grafts from donors pretreated with Dex and IL-2 led to longer survival times of the recipients and suppressed the effects of GVHD after allogeneic transplantation. Thus, GVHD can be suppressed by the specific expansion of regulatory T cells in the donor with Dex and IL-2 co-treatment.
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